Considerable evidence supports the targeting of melanocortin
receptors for the treatment of inflammation however little
pharmaceutical development has been reported. Receptor
subtypes in the melanocortin receptor family have recently
been characterized and the potential for developing more
effective and selective anti-inflammatory drugs is now
possible. This dossier:
> Overviews the development of melanocortin research
and the involvement of various receptor subtypes and their
ligands in immunological disorders
> Analyzes melanocortin receptor ligands currently in
pharmaceutical development
> Overviews the immunotherapy market
> Compares the potential of melanocortin ligands to
the exisitng market
> Identifies research tools for the development of
melanocortin ligands
> Suggests screening architectures for the development
of therapeutic candidates
> Offers practical input to help expedite the
screening process focussing on novel HTS/MTS assays designed
to reduce bench to clinic down-time and assays using human
material to fully characterize the clinical potential of
hits
> Lists field leaders
Publication date: 24th September 2001; 3000 words
About the Author: Dr Jon Goldhill has over 10 years of
academic and industrial research experience including 5
years in middle management at the French pharmaceutical
giants, Sanofi-Synthelabo. Focussing on a variety of
indications including inflammatory disorders, GI disease,
Urological conditions and cancer, Dr Goldhill was
responsible for target identification and project
development. Dr Goldhill is now CEO and chief analyst at
LeadDiscovery and coordinates the identification of
candidate drug discovery projects with industrial potential.
Price: $150.00 click
here
